Format

Send to

Choose Destination
Antiviral Res. 2016 Sep;133:23-31. doi: 10.1016/j.antiviral.2016.07.008. Epub 2016 Jul 20.

JNJ872 inhibits influenza A virus replication without altering cellular antiviral responses.

Author information

1
The Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Finland.
2
Institute of Biotechnology (BI), University of Helsinki, Finland; Finnish Institute of Occupational Health (TTL), Helsinki, Finland.
3
Institute of Biotechnology (BI), University of Helsinki, Finland.
4
Finnish Institute of Occupational Health (TTL), Helsinki, Finland.
5
The Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Finland. Electronic address: denis.kainov@helsinki.fi.

Abstract

JNJ-63623872 (formally known as VX-787; referred to here as JNJ872) is an orally bioavailable compound, which is in phase II clinical trials for the treatment of influenza A virus (IAV) infections. Here we show that JNJ872 inhibits at nanomolar concentrations the transcription of viral RNA in IAV-infected human macrophages by targeting a highly conserved site on the cap-snatching domain of influenza polymerase basic 2 protein (PB2). Furthermore, even lower concentrations of JNJ872 protected macrophages from IAV-mediated death when given in combination with 100 nM gemcitabine, which also attenuated transcription and replication of viral RNA. Importantly, treating human macrophages with JNJ872 allowed expression of many immune-related and other genes, involved in antiviral responses, such as indoleamine 2,3-dioxygenase 1 (IDO), and cytosolic 5'-nucleotidase 3A (NT5C3A). Moreover, our targeted metabolomics analysis indicate that treatment with JNJ782 did not interfere with metabolic responses to infection, which further supported our transcriptomics results. Thus, VX-737 alone or in combination with other drugs could be beneficial for treating IAV infected patients, because it would allow the development of antiviral responses and, thereby, protect individuals from current and future infections with closely related IAV strains.

PMID:
27451344
DOI:
10.1016/j.antiviral.2016.07.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center